We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

IDS LIMITED

Immunodiagnostic Systems Holdings PLC (IDS) develops, manufactures, and markets immunoassays and automated immunoanal... read more Featured Products: More products

Download Mobile App





IDS Exhibits Next Generation Automated Immunoanalyzer IDS-i10 at MEDICA 2019

By LabMedica International staff writers
Posted on 18 Nov 2019
Immunodiagnostic Systems {(IDS) Tyne & Wear, UK} exhibited its next generation automated immunoanalyser, the IDS-i10, at the 2019 edition of MEDICA, the world's largest trade fair for medical technology, held from 18 to 21 November in Düsseldorf, Germany. More...
At MEDICA 2019, IDS also discussed its unique panel of automated and manual assays, with experts available onsite to answer the visitors’ queries.

More than 5,000 exhibitors from 70 countries presented their newest products and ideas at MEDICA which drew 120,000 trade visitors from over 170 countries. In-patient and out-patient medicine, medical technology, diagnostic systems and electromedical and laboratory equipment were all on display throughout the event. The exhibition welcomed business, research and politics leaders, sharing their insights and findings with thousands of international experts. The immersive program also included a series of forums and conferences.

IDS develops, manufactures, and markets innovative immunoassays in both automated and manual formats. The company’s portfolio includes specialty testing solutions in the fields of Endocrinology, Autoimmunity, Allergy and Infectious Disease. The IDS-i10 next generation immunoanalyzer comes with faster testing capability and the capacity to connect to laboratory track systems, which can help medical professionals perform automated immunoassays more efficiently than ever. The chemiluminescence-based technology platform is entirely automated and offers continuous loading, as well as random access analysis.

Related Links:
Immunodiagnostic Systems


Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
Automatic CLIA Analyzer
Shine i6000
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.